One hundred and ninety subjects from 100 adult polycystic kidney disease (APKD) families on the North Western Regional Genetic Register were interviewed to determine the likely demand for prenatal diagnosis. A detailed questionnaire was used to assess understanding and experience of clinical, therapeutic, and genetic aspects of APKD. Major features of the disease (presence of renal cysts which can lead to renal failure) and forms of therapy (dialysis and transplantation) were known; knowledge of less common features was related to experience. The cohort had had genetic counselling and the majority knew the risk to their own offspring, although the mechanics of the mode of inheritance was often misunderstood. Uptake of presymptomatic ultrasound testing was high, and some implications of early diagnosis are noted. A minority changed their reproductive behaviour as a result of APKD, and although the majority felt a prenatal test should be available, only 23% at high risk of passing on the disease and contemplating children felt they would be interested, and so far only one request for prenatal diagnosis has been received. Thus, demand appears to be low and to be related to perception of the seriousness of APKD.
The condition is extremely variable. Some subjects maintain normal renal function into their 80s, others are affected neonatally,6 while the majority experience renal insufficiency by middle life. Whether neonatal APKD is aetiologically distinct from adult onset APKD has yet to be determined. 7 APKD is characterised by bilateral renal cysts, usually leading to renal insufficiency by the fifth to sixth decades of life. The commonest manifestations are pain, hypertension, urinary tract infections, and haematuria with palpable kidneys.8 9 APKD patients account for about 10% of all those on dialysis,'0 and it has been estimated that 2% of affected subjects will develop end stage renal failure by the age of 40, 23% by the age of 50, and 48% by the age of 70. " Transplantation is a valid treatment for APKD patients in renal failure. Liver cysts are present in about 30% of patients, and cysts may also occur in the pancreas, spleen, lung, and ovary.'2 The liver cysts have been considered to be benign, but there is evidence that they can cause severe problems. 13 Cardiovascular abnormalities have been noted,'4 and the association of intracranial aneurysms leading to cerebral haemorrhage is well documented.'5 16 Children of affected persons have a 50% risk of carrying the gene, and young people making reproductive decisions are often concerned to know their carrier status. Intravenous urography, nephrotomography, radionuclide scanning, arteriography, and computed tomography have all been previously used to assess carrier status. The current preferred method is ultrasonography. 1-'9 It is painless and noninvasive, but its accuracy at an age when most people are making reproductive decisions has been questioned. 20 Although ultrasound screening of potential gene carriers is well established, prenatal diagnosis is not. Cysts may occasionally be detected prenatally by ultrasonography, but then only in the third trimester of pregnancy.21 22 A major advance in the study of APKD was made by the discovery of a gene probe closely linked to the disease locus on the short arm of chromosome 16.23 Results obtained using the 3'HVR probe of Reeders have a 5% error rate because of recombination. A Adult polvcvstic kidnev disease: knowledge, experience, and attitudes to prenatal diagnosis second bridging marker (24-1) has now been described,24 which, used together with the 3'HVR marker, gives an error rate of less than 1%. The possibility ofgenetic heterogeneity has been raised,25 26 but so far has not been resolved.27 2x
Application of these DNA markers permits both carrier detection and prenatal diagnosis in families with suitable pedigree structures; the first prenatal diagnosis for APKD using linked probes was carried out in 1986.29 Now that prenatal diagnosis is possible, the question arises of whether it will be an acceptable option to couples, given the late onset (4) information regarding affected relatives, (5) presymptomatic, and (6) prenatal testing.
For sections (2) and (3) 
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Overall knowledge scores were tabulated bv adding the scores for each feature mentioned and then put into the following categories: 0=absent, l-5=poor, 6-12=fair, 13-17=good. 18+=excellent. Overall knowledge scores were tabulated by adding the scores for each form of therapy mentioned and then put into the following categories: 0=absent, 1-3=poor, 4-6=fair, 7-9=good, 10+= excellent. Overall knowledge scores were tabulated by adding the scores for each feature mentioned and then put into the following categories: 0=absent, 1-2=poor, 3-8=fair, 9-11=good, 12+=excellent. disease, far fewer persons knew of the increased risk of high blood pressure, urinary tract infections (UTI), and haematuria, and these were those who had had experience of these, either personally or within the family. Only nine (5%) mentioned the increased possibility of subarachnoid haemorrhages (SAH), one of the more severe complications of APKD. Each of these was from a family in which SAHs had occurred. Forty-two (22%) had a clinical knowledge score considered good or excellent, while 26 (14%) had poor or absent knowledge (figure). None of the 15 high risk subjects had good or excellent knowledge and five (33%) had poor or absent knowledge.
KNOWLEDGE OF THERAPY
In response to direct questions, 157 (83%) subjects knew of the availability of transplantation, and 155 (82%) of the possibility of dialysis (table lb) Subjects were then asked whether they themselves would be interested in a prenatal test for APKD (table  5) : 55 (29%) of the whole cohort said they would compared with' 21 (25%) of those affected and two (13%) of those at high risk. Interestingly, of the low risk group, for whom the question was hypothetical, 47% responded in the affirmative. Of the 55 who felt that they would be interested in a prenatal test, only 23 (19 females, four males) were in fact affected or at high risk and, of these, only nine were actually planning a family at the time of the study. Of these nine, eight were female and seven had no children to date.
Looking at the relationship between perception of the severity of APKD and interest in a prenatal test, 65% of those personally interested in a test, and at high risk of passing on the gene, considered the disease to be 'extremely serious' compared with 34% of the affected/high risk group not interested in a test. Although the perception of the disease differs in these twogroups, the objective assessmentoftheir experience in their own relatives did not differ between the two groups. Of the whole cohort, 50% felt the disease to be 'extremely serious'.
Subjects were asked an open ended question about Patients with APKD are at increased risk of subarachnoid haemorrhages from rupture of intracranial aneurysms. It is usually accepted that to screen all affected subjects using cerebral arteriography is not necessary, owing to the associated risk of the technique, although newer, non-invasive measures may change this.' Only nine subjects in our cohort knew of the risks of this potentially lethal complication, which underlies a reluctance to discuss this aspect with subjects from families in which SAHs have not occurred. Our nine subjects all came from two families in which more than one person has been affected by this complication. Despite genetic counselling, and the long term follow up of a genetic register, knowledge of the genetic aspects was found to be variable, and indicated particular areas of misunderstanding. However, 73% of subjects correctly recalled the risk to their offspring, suggesting that while mechanisms of inheritance may not be recalled, the pertinent risk figure is. Furthermore, the knowledge of genetic aspects was better in APKD family members than it was in their spouses. Misinterpretation, or poor recall after genetic counselling, can result from many factors, including the emotional readiness at the time of counselling, the ability to remember the facts given, and the style and time taken by the counsellor. In particular, it may be that the use of diagrams to help with a full explanation of the mode of inheritance would decrease common misunderstandings; the linkage diagrams we have devised proved particularly useful when explaining the use of linked probes within families and the problems associated with recombination.
Of the 132 subjects from the cohort who were at prior risk of inheriting APKD, 81% had had some form of presymptomatic testing for the presence of APKD, a figure at variance with the reported uptake of genetic presymptomatic testing for Huntington's chorea,32 even though both conditions are dominant and have an adult onset. This difference is probably the result in part of the well known availability of effective treatment for APKD. The availability of a non-invasive ultrasound scan for presymptomatic diagnosis will probably mean that DNA presymptomatic screening may not have the same immediate impact in APKD as it will for conditions where DNA provides the only possibility for presymptomatic tests, or where existing tests are more invasive, for example, polyposis coli. However, the impact of genetic screening for APKD will be more important for those who have negative scans in their early 20s and want to make reproductive decisions. In these cases, the results of ultrasound, and linkage can be combined.27 The use of linked probes for APKD will allow earlier testing, with greater accuracy (assuming the question of genetic heterogeneity is resolved). A total of 19% of this cohort felt that a test which was either more accurate, or could be done at an earlier age, would be preferable to the ultrasound test.
Of those subjects at prior risk of inheriting APKD, only eight declined ultrasound screening. However, among the APKD families generally, this figure is probably much higher, as 81% of the high risk subjects who were asked to participate declined. Clearly the choice not to have testing, and not to participate in the study, reflects their attitude towards the risk of the disease. It is important to remember that the very high uptake of presymptomatic testing in our cohort does partially represent a bias of subject participation very common in surveys of this sort.33 3 However, even if all of the high risk group had participated, uptake would have been at least 64% in the group as a whole.
The diagnosis of an adult onset condition many years before the onset of symptoms could potentially have major adverse consequences. These include the possibility of discrimination in employment and financial matters (for example, life insurance) as well as the psychological impact of the result, and this has been discussed in relation to presymptomatic testing for other autosomal dominant conditions, such as Huntington's chorea. 35 In this study 33% of those diagnosed presymptomatically had experienced problems with insurance, and 74% described feeling depressed or having changes in behaviour after diagnosis. As one subject said: "When I was positive, the cysts were visible on the screen, I came face to face with my own mortality". Although three-quarters felt they had experienced adverse psychosocial consequences after a presymptomatic test, we did not seek detailed information on the nature and extent of psychological sequelae to a positive diagnosis.
We were interested to know what effect, it any, APKD had had on reproductive behaviour. Although the cohort considered this a serious disease, and had a good recall of the risk to their offspring, only 17% of the affected group had in fact had no children or limited their families because of the risk. This group proportionally had a greater understanding of the clinical aspects, the therapy, and the genetics than the affected group as a whole, and when asked which factors had most influenced their decision regarding children, they cited a reluctance to watch their own offspring suffer with kidney problems ("I had a vision of all my children lined up on kidney machines"), a feeling that they wouldn't want a child to have to make the same adult decisions (both in terms of career and reproduction) as themselves, and the guilt which they would have to contend with if the condition were passed on.
A majority of the cohort felt that the development of a prenatal test was acceptable, although a minority of the cohort said they would personally be interested. Almost half of the cohort felt that APKD was not a valid reason for terminating a pregnancy, while only 9% disagreed with termination generally. Comments such as "I'm not ill. If the child turns out to be as well and fit as me then it won't be bad" were very common. Clearly the adult onset, partially treatable nature of the condition makes termination of pregnancy a less acceptable choice than for seriously handicapping conditions apparent in newborns or children. A higher proportion of those at low genetic risk indicated that they would have had a prenatal test for APKD if they had been at high risk; it would seem that prenatal diagnosis may be more appealing in the abstract. Of those at risk of passing the APKD gene on to their offspring, and currently considering having children, nine (23%) said they would be interested in a prenatal test and only one has actively pursued the matter.
About half of those family members invited to participate in the study agreed to be interviewed; therefore study bias must be considered. However, one would imagine that persons willing to participate in a study would be more openly facing the disease and its implications than those not willing to participate, and therefore it would be difficult to imagine that those not interviewed would be more likely to want prenatal diagnosis.
Comparing the groups who would accept/not accept prenatal diagnosis, no differences in knowledge scores were noted, but those who would accept prenatal diagnosis were more likely to perceive the disease as serious, even though the objective experiences of the disease were not different.
We conclude that even for persons with a realistic perception of the disease, and a good recall of the recurrence risk, the demand for prenatal diagnosis will be low.
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